China bans clinical research in germline genome editing as ‘irresponsible’
By Alcott Wei,
South China Morning Post
| 07. 13. 2024
China has banned all clinical research involving germline genome editing under a newly released ethics guideline.
Germline gene engineering relates to altering the DNA in sperm, eggs or early embryos to introduce changes that can be inherited.
“Any clinical research involving germline genome editing is irresponsible and not permitted,” according to the Ethical Guideline for Human Genome Editing Research, released earlier this week by China’s Ministry of Science and Technology.
The guideline marks the latest effort from China to tighten ethics reviews and regulations after bioscientist He Jiankui shocked the world in 2018 with the announcement that he had created twin gene-edited babies to make them less vulnerable to HIV/Aids.
“Only when benefits, risks and alternative options are fully understood and weighed, when issues of safety and efficacy are addressed, broad social consensus is reached and rigorous evaluation is conducted, could clinical research be considered with strict supervision in place,” the guideline adds.
It also strictly prohibits the use of genome editing research on germ cells, fertilised eggs, or human embryos for reproductive purposes.
“The potential detrimental impacts and risks...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Ed Cara, Gizmodo | 06.22.2025
In late May, several scientific organizations, including the International Society for Cell and Gene Therapy (ISCT), banded together to call for a 10-year moratorium on using CRISPR and related technologies to pursue human heritable germline editing. The declaration also outlined...
By Isabel van Brugen, Newsweek | 06.05.2025
A U.S.-based biotech company has unveiled a new in vitro fertilization (IVF) option that allows parents to select embryos based on genetic markers tied to health and longevity.
DNA testing and analysis company Nucleus Genomics has announced the world's first...
By Jonathan D. Grinstein, PhD, Inside Precision Medicine | 06.03.2025
On Tuesday, 307 days after he was first admitted to Children’s Hospital of Philadelphia (CHOP), KJ Muldoon went home after being successfully treated with the first personalized CRISPR gene editing therapy. KJ, who was born with a serious and...